+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin-induced myopathy: a review and update



Statin-induced myopathy: a review and update



Expert Opinion on Drug Safety 10(3): 373-387



Statin-induced myopathy is an important cause of statin intolerance and the most common cause of statin discontinuation. Observational studies estimate that 10 - 15% of statin users develop statin-related muscle side effects ranging from mild myalgia to more severe muscle symptoms with significant CPK elevations. This article reviews the epidemiology, clinical features, risk factors and mechanisms of statin-induced myopathy and provides an evidence-based algorithm for managing patients with statin myopathy. There are multiple risk factors for statin-induced myopathy that are both patient-related (age, genetics, co-morbidities) and drug-related (statin metabolism via the CYP system, drug-drug interactions and statin drug transport). Management options for statin-intolerant patients include statin switching, especially to low-dose, non-daily doses of long-acting statins, such as rosuvastatin and atorvastatin, and other non-statin lipid-lowering agents, such as ezetimibe and colesevelam, and possibly red yeast rice. In conclusion, statin-induced myopathy is a significant clinical problem that contributes considerably to statin therapy discontinuation. However, there exist multiple and effective management options for statin intolerant patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911594

Download citation: RISBibTeXText

PMID: 21342078

DOI: 10.1517/14740338.2011.540568


Related references

Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmunity Reviews 12(12): 1177-1181, 2014

Statin myopathy: an update. Current Opinion in Rheumatology 18(6): 647-653, 2006

Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment. Journal of Pharmacy Practice (): -, 2016

Large copy-number variations in patients with statin-associated myopathy affecting statin myopathy-related loci. Physiological Research (): -, 2016

Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants. Journal of Pharmacogenomics & Pharmacoproteomics 5(2): -, 2014

Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. Plos One 3(6): E2522-E2522, 2008

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. Molecular Diagnosis & Therapy (): -, 2016

Economic Evaluation Of A Pharmacogenomic Test For Statin-Induced Myopathy In Cardiovascular High-Risk Patients Initiating A Statin. Value in Health 18(7): A396-A396, 2015

An Unusual Case of Statin-Induced Myopathy: Anti-HMGCoA Necrotizing Autoimmune Myopathy. Journal of General Internal Medicine 30(12): 1879-1883, 2016

Forcibly increasing carbohydrate oxidation by pharmacological activation of the pyruvate dehydrogenase complex reduces statin mediated upregulation of FOXO gene targets and protects against statin-induced myopathy in rodent skeletal muscle. 2012

Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 39(1): 90-98, 2009

Statin myopathy: a review of recent progress. Current Opinion in Rheumatology 22(6): 644-650, 2011

Narrative review: statin-related myopathy. Annals of Internal Medicine 150(12): 858-868, 2009

Statin-induced Myopathy. Global Advances in Health and Medicine 1(2): 32-36, 2012

Statin-induced myopathy. Cardiovascular Journal of Africa 19(3): 156-157, 2008